MERIENNE, Camille; ROUSSET, Marine; DUCINT, D.; CASTAING, N.; TITIER, Karine; MOLIMARD, Mathieu; BOUCHET, Stephane

doi:10.1016/j.jpba.2017.11.060

Metadatos

Mostrar el registro completo del ítem

Licencia de uso del documento

MERIENNE, Camille
Bordeaux population health [BPH]

ROUSSET, Marine
Bordeaux population health [BPH]

DUCINT, D.

Idioma

Article de revue

Este ítem está publicado en

Journal of Pharmaceutical and Biomedical Analysis. 2018-02-20, vol. 150, p. 112-120

Resumen en inglés

Several studies have shown that therapeutic drug monitoring of tyrosine kinase inhibitors (TKI) can improve their benefit in cancer. An analytical tool has been developed in order to quantify 17 tyrosine kinase inhibitors and 2 metabolites in human plasma (afatinib, axitinib, bosutinib, crizotinib, dabrafenib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, ponatinib, regorafenib, regorafenib M2, regorafenib M5, ruxolitinib, sorafenib, sunitinib, vandetanib). Drugs were arranged in four groups, according to their plasma concentration range: 0.1-200ng/ml, 1-200ng/ml, 4-800ng/ml and 25-5000ng/ml. Solid phase extraction was used and separation was performed with HPLC using a gradient system on a solid core particle C18 column (5x2.1mm, 1.6mum). Ions were detected with a triple quadrupole mass spectrometry system. This assay allows rapid determination of 19 TKI in less than 5min per run. This high throughput routine method will be useful to adjust doses of oral anticancer drugs in order to improve treatments efficacy.< Leer menos

Palabras clave en inglés

PharmacoEpi-Drugs

Metadatos

Compartir este ítem

Licencia de uso del documento

High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS/MS

Idioma

Este ítem está publicado en

Resumen en inglés

Palabras clave en inglés

URI

DOI

Centros de investigación